RBC Capital Mkts initiated coverage on Avidity Biosciences with a new price target
$RNA
Biotechnology: Pharmaceutical Preparations
Health Care
RBC Capital Mkts initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $67.00